215 related articles for article (PubMed ID: 26218530)
1. Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.
Messaoudene M; Périer A; Fregni G; Neves E; Zitvogel L; Cremer I; Chanal J; Sastre-Garau X; Deschamps L; Marinho E; Larousserie F; Maubec E; Avril MF; Caignard A
PLoS One; 2015; 10(7):e0133363. PubMed ID: 26218530
[TBL] [Abstract][Full Text] [Related]
2. Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma.
Messaoudene M; Fregni G; Fourmentraux-Neves E; Chanal J; Maubec E; Mazouz-Dorval S; Couturaud B; Girod A; Sastre-Garau X; Albert S; Guédon C; Deschamps L; Mitilian D; Cremer I; Jacquelot N; Rusakiewicz S; Zitvogel L; Avril MF; Caignard A
Cancer Res; 2014 Jan; 74(1):81-92. PubMed ID: 24225017
[TBL] [Abstract][Full Text] [Related]
3. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
4. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.
Vuylsteke RJ; Molenkamp BG; van Leeuwen PA; Meijer S; Wijnands PG; Haanen JB; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2006 May; 12(9):2826-33. PubMed ID: 16675577
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
[TBL] [Abstract][Full Text] [Related]
8. The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique.
Rutkowski P; Szydłowski K; Nowecki ZI; Sałamacha M; Goryń T; Mitręga-Korab B; Pieńkowski A; Dziewirski W; Zdzienicki M
World J Surg Oncol; 2015 Oct; 13():299. PubMed ID: 26462471
[TBL] [Abstract][Full Text] [Related]
9. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
[TBL] [Abstract][Full Text] [Related]
10. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.
Wat H; Senthilselvan A; Salopek TG
J Am Acad Dermatol; 2016 Jan; 74(1):94-101. PubMed ID: 26542815
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
Han D; Zager JS; Shyr Y; Chen H; Berry LD; Iyengar S; Djulbegovic M; Weber JL; Marzban SS; Sondak VK; Messina JL; Vetto JT; White RL; Pockaj B; Mozzillo N; Charney KJ; Avisar E; Krouse R; Kashani-Sabet M; Leong SP
J Clin Oncol; 2013 Dec; 31(35):4387-93. PubMed ID: 24190111
[TBL] [Abstract][Full Text] [Related]
12. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
[TBL] [Abstract][Full Text] [Related]
13. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
14. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
15. Distribution of several activating and inhibitory receptors on CD3(-)CD56(+) NK cells in regional lymph nodes of melanoma patients.
Vuletić A; Jurišić V; Jovanić I; Milovanović Z; Nikolić S; Konjević G
J Surg Res; 2013 Aug; 183(2):860-8. PubMed ID: 23522458
[TBL] [Abstract][Full Text] [Related]
16. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
[TBL] [Abstract][Full Text] [Related]
17. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph-node biopsy for melanoma of the trunk and extremities: the McGill experience.
Tremblay F; Louffi A; Shibata H; Meterissian S
Can J Surg; 2001 Dec; 44(6):428-31. PubMed ID: 11764875
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results.
Vuylsteke RJ; van Leeuwen PA; Statius Muller MG; Gietema HA; Kragt DR; Meijer S
J Clin Oncol; 2003 Mar; 21(6):1057-65. PubMed ID: 12637471
[TBL] [Abstract][Full Text] [Related]
20. Staging patients with cutaneous malignant melanoma by same-day lymphoscintigraphy and sentinel lymph node biopsy: a single-institutional experience with emphasis on recurrence.
Gad D; Høilund-Carlsen PF; Bartram P; Clemmensen O; Bischoff-Mikkelsen M
J Surg Oncol; 2006 Aug; 94(2):94-100. PubMed ID: 16847917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
